6 recruiting, 1 active not recruiting, 1 completed. 6 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 6 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow HER2 Low Breast Carcinoma: new trials by email Literature Review of HER2 Low Breast Carcinoma trials Research Report on HER2 Low Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positiveļ¼ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Culmerciclib, Aromatase Inhibitor (AI) - Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-09-14 | 2026-09-15 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Recruiting | Laura Huppert, MD, BA | 36 | 2026-06-05 | 2026-06-11 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Patritumab deruxtecan, Olaparib - Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 152 | 2024-03-21 | 2026-09-04 |
| Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel - Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer | Phase 3 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 160 | 2024-01-17 | 2026-10-27 |
| A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer SHR-A1811 for injection - HER2 Low Breast Carcinoma | Phase 2 | Recruiting | Henan Cancer Hospital | 66 | 2023-07-05 | 2024-11-04 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients immunohistochemistry (IHC) and in situ hybridization (ISH) Test - HER2 Low Breast Carcinoma | Completed | Mahdis Bayat | 3582 | 1991-04-01 | 2023-03-03 |
Breast Neoplasms (5) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Rectal Neoplasms (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Breast Neoplasms (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms by Histologic Type (1)
ALX148 (1) · ARX788 (1) · Amiloride (1) · Aromatase Inhibitors (1) · Cyclophosphamide (1) · Doxorubicin (1) · Epirubicin (1) · Immunohistochemistry (1) · In Situ Hybridization (1) · Injections (1) · Paclitaxel (1) · RAD1901 (1) · Specimen Handling (1) · elacestrant (1) · olaparib (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Henan Cancer Hospital (1) · Kristina A. Fanucci (1) · Laura Huppert, MD, BA (1) · Mahdis Bayat (1) · QuantumLeap Healthcare Collaborative (1)
China (3) · United States (3) · France (1)
Chang Gong (1) · Chang Gong, Prof (1) · Kristina Fanucci, MD (1) · Laura Huppert, MD (1) · Mohammad Esmail Akbari, Professor (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Zhenzhen Liu, PhD (1)
PMID 16622270, PMID 18997125, PMID 24529560, PMID 26297356, PMID 28135148, PMID 30307466, PMID 31838010, PMID 32330069, PMID 33507815, PMID 34902335, PMID 35020204, PMID 35337692, PMID 36821125, PMID 37794050, PMID 38751537, PMID 41413016, PMID 42811016
2023 (1)